ADMA Biologics, Inc. (NASDAQ:ADMA) Director Lawrence P. Guiheen Sells 9,000 Shares

ADMA Biologics, Inc. (NASDAQ:ADMA) Director Lawrence P. Guiheen sold 9,000 shares of the company’s stock in a transaction dated Monday, September 9th. The shares were sold at an average price of $18.47, for a total transaction of $166,230.00. Following the transaction, the director now owns 153,941 shares in the company, valued at approximately $2,843,290.27. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at the SEC website.

ADMA Biologics Stock Down 2.2 %

ADMA Biologics stock traded down $0.38 during midday trading on Wednesday, hitting $16.91. 5,468,410 shares of the stock were exchanged, compared to its average volume of 3,115,505. ADMA Biologics, Inc. has a 52-week low of $3.06 and a 52-week high of $19.34. The company has a quick ratio of 2.80, a current ratio of 6.87 and a debt-to-equity ratio of 0.74. The business’s 50-day moving average price is $14.69 and its 200-day moving average price is $10.27. The stock has a market capitalization of $3.94 billion, a price-to-earnings ratio of -865.50 and a beta of 0.61.

ADMA Biologics (NASDAQ:ADMA) last released its earnings results on Thursday, August 8th. The biotechnology company reported $0.13 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.08 by $0.05. ADMA Biologics had a return on equity of 38.79% and a net margin of 10.53%. The company had revenue of $107.20 million during the quarter, compared to analyst estimates of $86.44 million. During the same period in the prior year, the company posted ($0.02) earnings per share. ADMA Biologics’s quarterly revenue was up 78.4% on a year-over-year basis. On average, research analysts expect that ADMA Biologics, Inc. will post 0.49 EPS for the current fiscal year.

Institutional Investors Weigh In On ADMA Biologics

A number of hedge funds have recently made changes to their positions in the business. Quest Partners LLC bought a new position in ADMA Biologics during the second quarter valued at about $29,000. EntryPoint Capital LLC bought a new position in shares of ADMA Biologics during the 1st quarter valued at approximately $31,000. Simplicity Wealth LLC purchased a new stake in shares of ADMA Biologics during the 1st quarter worth approximately $68,000. Oxford Asset Management LLP bought a new stake in shares of ADMA Biologics in the 4th quarter worth approximately $83,000. Finally, CWM LLC lifted its stake in ADMA Biologics by 114.2% in the second quarter. CWM LLC now owns 8,192 shares of the biotechnology company’s stock valued at $92,000 after purchasing an additional 4,367 shares during the last quarter. 75.68% of the stock is currently owned by institutional investors.

Analysts Set New Price Targets

A number of analysts recently commented on the company. Mizuho boosted their target price on ADMA Biologics from $12.00 to $14.00 and gave the company a “buy” rating in a research report on Thursday, June 20th. HC Wainwright boosted their price objective on ADMA Biologics from $10.00 to $18.00 and gave the stock a “buy” rating in a report on Monday, August 12th. Finally, Cantor Fitzgerald raised their target price on ADMA Biologics from $15.00 to $20.00 and gave the company an “overweight” rating in a report on Friday, August 9th. One equities research analyst has rated the stock with a hold rating, three have issued a buy rating and one has issued a strong buy rating to the company’s stock. According to data from MarketBeat, the stock currently has a consensus rating of “Buy” and a consensus price target of $15.50.

About ADMA Biologics

ADMA Biologics, Inc, a biopharmaceutical company, engages in developing, manufacturing, and marketing specialty plasma-derived biologics for the treatment of immune deficiencies and infectious diseases in the United States and internationally. The company offers BIVIGAM, an intravenous immune globulin (IVIG) product indicated for the treatment of primary humoral immunodeficiency (PI); ASCENIV, an IVIG product for the treatment of PI; and Nabi-HB for the treatment of acute exposure to blood containing Hepatitis B surface antigen and other listed exposures to Hepatitis B.